Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

63.83 +0.73 (+1.16%)

Streaming Delayed Price Updated: 10:46 AM EDT, Jul 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

91 92 Next >

Dow Falls Over 150 Points After Powell's Comments On Rate Cuts: Investor Sentiment Declines, But Fear Index Remains In 'Greed' Zone ↗

July 31, 2025

US stocks fell on Wednesday, with the Dow dropping over 150 points after Fed Chair Powell's comments. Fear Index remained in Greed zone.

Via Benzinga

Topics Economy Stocks

Microsoft, Apple And 3 Stocks To Watch Heading Into Thursday ↗

July 31, 2025

U.S. stock futures up, Apple, Amazon, Meta report strong earnings, Microsoft beats forecast, Bristol-Myers Squibb to release results.

Via Benzinga

Bristol Myers Squibb: A Stock with Potential Amid Challenges ↗

July 30, 2025

Via The Motley Fool

Bristol-Myers Squibb Earnings Preview ↗

July 30, 2025

Via Benzinga

Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever ↗

July 30, 2025

Being a great investor doesn't have to be complicated or expensive.

Via The Motley Fool

Topics Intellectual Property

Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here's What Investors Are Thinking ↗

July 18, 2025

Via Stocktwits

3 Low-Volatility Stocks We Find Risky

July 30, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Bristol-Myers Squibb (BMY) Q2 Earnings: What To Expect

July 29, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

July 28, 2025

From Bristol Myers Squibb

Via Business Wire

Why Is ATAI Life Sciences Stock Trading Lower On Monday? ↗

July 28, 2025

Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a favorable safety profile.

Via Benzinga

Biotech Is Booming, and This Undervalued REIT Stands to Gain ↗

July 25, 2025

Via The Motley Fool

Explore the top gainers and losers within the S&P500 index in today's session. ↗

July 25, 2025

Let's delve into the developments on the US markets in the middle of the day on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Via Chartmill

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

July 25, 2025

From Bristol Myers Squibb

Via Business Wire

Warren Buffett Owns 10 High-Yield Dividend Stocks. Here's the Best of the Bunch. ↗

July 25, 2025

Via The Motley Fool

2 Cash-Producing Stocks to Keep an Eye On and 1 We Find Risky

July 25, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

Topics Economy

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

July 24, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus Pharmaceuticals (NASDAQ:SUPN) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000' ↗

July 24, 2025

On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings.

Via Benzinga

Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks

July 23, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks

July 23, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Peering Into Bristol-Myers Squibb's Recent Short Interest ↗

July 23, 2025

Via Benzinga

A Look Into Bristol-Myers Squibb Inc's Price Over Earnings ↗

July 22, 2025

Via Benzinga

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗

July 22, 2025

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

Via Benzinga

Topics Government

Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock ↗

July 22, 2025

The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment.

Via Investor's Business Daily

FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks ↗

July 22, 2025

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

Via Benzinga

3 Value Stocks We’re Skeptical Of

July 22, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

July 21, 2025

Via Benzinga

Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

July 21, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial ↗

July 18, 2025

Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in myelofibrosis patients.

Via Benzinga

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

July 18, 2025

From Bristol Myers Squibb

Via Business Wire

Unpacking Q1 Earnings: Organon (NYSE:OGN) In The Context Of Other Branded Pharmaceuticals Stocks

July 17, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

91 92 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.